News | April 26, 2021
Lonza will invest CHF 200 mn to construct manufacturing complex
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
India produces 60% of the world’s vaccine
The vaccine was 85 percent effective in preventing severe disease across all regions.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Subscribe To Our Newsletter & Stay Updated
